Global Custom Market Research Reports Provider Company

phone

ATUM - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 22
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

ATUM, formerly DNA2.0 Inc is a bioengineering company that provide platforms for protein and vector engineering solutions. The company develops and offers synthetic biology solutions. Its products include expression vectors, electra system, CRISPR/Cas9, proteinpaintbox, cell strains and reagents. ATUM offers services such as gene synthesis, protein engineering, expression optimization, and vector engineering. The company provides antibody to developing enzymes for commercial drug and biofuel manufacture. It provides synthetic biology tools that include gene designer, GRNA designer, DNA atlas, bioinformatic, toolbox and literature database. The company serves academic, government and the pharmaceutical, chemical, agricultural and biotechnology industries. It operates through its office located in the US and Europe. ATUM is headquartered in Newark, California, the US.

ATUM - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 4
List of Figures 4
ATUM, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ATUM, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ATUM, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ATUM, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
ATUM, Pharmaceuticals & Healthcare, Deal Details 9
Partnerships 9
Pareto Biotech Enters into Technology Integration Agreement with DNA2.0 9
DNA2.0 Enters Into Research Agreement With St Georges University Of London For Production Of Therapeutic Antibodies 10
DNA2.0 Enters Into Research Agreement With Newcastle University For Bacillus subtillis Expression System 11
DNA2.0 And Aldevron Enter Into Agreement For Insect Cell Expression System 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
Licensing Agreements 14
Just Biotherapeutics Enters into Licensing Agreement with ATUM 14
ATUM Enters into Licensing Agreement with Horizon Discovery 15
Horizon Discovery Enters into Licensing Agreement with ATUM 16
Acquisition 17
DNA2.0 to Acquire MIGS 17
ATUM - Key Competitors 18
ATUM - Key Employees 19
ATUM - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Other Significant Developments 21
Apr 10, 2017: ATUM Launches Cell-Line Development Service 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List Of Tables

List of Tables
ATUM, Pharmaceuticals & Healthcare, Key Facts 2
ATUM, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
ATUM, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ATUM, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ATUM, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ATUM, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Pareto Biotech Enters into Technology Integration Agreement with DNA2.0 9
DNA2.0 Enters Into Research Agreement With St Georges University Of London For Production Of Therapeutic Antibodies 10
DNA2.0 Enters Into Research Agreement With Newcastle University For Bacillus subtillis Expression System 11
DNA2.0 And Aldevron Enter Into Agreement For Insect Cell Expression System 12
Pfenex Enters Into Co-Development Agreement With DNA2.0 13
Just Biotherapeutics Enters into Licensing Agreement with ATUM 14
ATUM Enters into Licensing Agreement with Horizon Discovery 15
Horizon Discovery Enters into Licensing Agreement with ATUM 16
DNA2.0 to Acquire MIGS 17
ATUM, Key Competitors 18
ATUM, Key Employees 19
ATUM, Subsidiaries 20

List Of Figures

List of Figures
ATUM, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ATUM, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ATUM, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ATUM, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ATUM, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ATUM, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

The global market size of Hypericum Perforatum Extract is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

Physiomics plc (Physiomics) is a computational systems biology services company. It is involved in developing outsourced systems and computational systems biology models for predicting and understanding cancer drug efficacy from

View Report

Pharmstandard develops, manufactures and distributes pharmaceutical products. The company offers prescription pharmaceuticals and over-the drug (OTC) pharmaceuticals. It also provides active pharmaceutical ingredients and contract manufacturing services. Pharmstandards product portfolio

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports